NEW #BladderCancer may, in part, be the result of how our cells respond to a very common childhood #infection with #BKvirus, also known as Human polyomavirus 1, according to new work from Dept of #Biology researchers at the @york.ac.uk .
www.linkedin.com/posts/drmelv...

THE JULY ISSUE IS ONLINE!!

How can we find a balance between Tacrolimus, BK virus and HLA?

Check it out here: shorturl.at/VwJnS

#july #issue #balance #tacrolimus #HLA #BKvirus @esottransplant.bsky.social

Study identifies modifiable risk factors for BK virus complications after kidney transplantation Read more about the study!

#BKvirus can harm #kidney transplants. Which risks can be changed❓

#MedUniVienna analysed ~197,000 cases: some drugs raise risk, but it’s the interaction + immune fitness that matter.

Published in @kidneyint.bsky.social​

Eurofins Transplant WTC 2025 – San Francisco, CA – Eurofins Transplant Diagnostics

🥩 REGISTER: eurofinstransplant.com/events/eurof...

🍷 Space is limited — RSVP now to secure your spot!
🦐 Monday, Aug 4th | 7-10pm

#ATC2025 #WorldTransplantCongress #BKvirus #polyomavirus #BKV #StemCell

A systematic literature review and meta-analysis evaluated modifiable risk factors for the development of BK polyoma virus-associated complications

doi.org/10.1016/j.kint.2025.06.014

#MedSky #NephSky #kidneytransplantation #bkvirus #TxID

Das #BKVirus verursacht Erkältungssymptome & bleibt nach der Erstinfektion meist inaktiv, kann aber bei Immunschwäche reaktiviert werden. Ob Prävention oder Behandlung hilft, eine transplantierte Niere zu schützen & die Viruslast zu senken, untersucht ein #CochraneReview: buff.ly/WOVqovk

Nonclinical and clinical characterization of MAU868, a novel human-derived monoclonal neutralizing antibody targeting BK polyomavirus VP1 Reactivation of BK polyomavirus (BKPyV) can cause significant kidney and bladder disease in immunocompromised patients. There are currently no effective, BKPyV-specific therapies. MAU868 is a novel, human immunoglobulin (Ig) G1 monoclonal antibody that binds the major capsid protein, VP1, of BKPyV with picomolar affinity, neutralizes infection by the 4 major BKPyV genotypes (EC50 ranging from 0.009-0.093 μg/mL; EC90 ranging from 0.102-4.160 μg/mL), and has comparable activity against variants with highly prevalent VP1 polymorphisms.

Excited to see how this mAB against the VP1 component of the BK virus performs in next RCT phases #bkvirus #txid

www.amjtransplant.org/article/S160...